Objective: To evaluate the 12-month clinical and functional outcomes in patients with schizophrenia who received RLAI treatment and were enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) in Australia and Belgium, and the Schizophrenia Outcomes Utilization, Relapse, and Clinical Evaluation (SOURCE) in the United States. Methods: e-Star and SOURCE are long-term, prospective, observational studies of patients with schizophrenia who commence RLAI treatment. Data are collected both retrospectively and prospectively and clinical effectiveness was measured by the Clinical Global Impression Severity (CGI-S) scale and patient functioning was measured by the Global Assessment of Functioning (GAF) scale. Results: Seven hundred sixty-nine patients (Australia=493, Belgium=163, USA=113) with 12-months of follow-up data were included. Australia had significantly younger patients than Belgium and the United States(mean ages: Australia=38.6, Belgium=41.6, USA=43.5; p=0.0003). Time since diagnosis (in years) was significantly higher in the United States than Australia and Belgium (USA=17.6, Australia=11.6, Belgium=9.8; p<0.0001). United Stats patients had significantly higher baseline GAF scores than the Australian and Belgian patients (USA=50.9, Australia=42.7, Belgium=43.1; p<0.0001). Despite baseline differences, GAF and CGI-S scores at 12-months for patients treated with RLAI significantly improved from baseline in all three countries. CGI-S scores significantly decreased by 0.8 (p<0.001), 1.08 (p<0.001) and 0.83 (p<0.001) points and GAF scores significantly increased by 12.7 (p<0.001), 14.8 (p<0.001), and 11.1 (p<0.001) points in Australia, Belgium, and the United States respectively. Conclusion: This interim analysis from the two observational studies shows that despite differences in patient characteristics among countries, treatment with RLAI resulted in significant improvements in disease severity and patient functioning in patients with schizophrenia from all three countries.